Superficial thrombophlebitis in ipsilateral breast after COVID-19 vaccination

Shima Aran; Orest O Kayder; Teena Chopra; Hani Abujudeh

doi:10.1016/j.radcr.2022.05.018

Superficial thrombophlebitis in ipsilateral breast after COVID-19 vaccination

Radiol Case Rep. 2022 Jun 13;17(8):2883-2887. doi: 10.1016/j.radcr.2022.05.018. eCollection 2022 Aug.

Authors

Shima Aran¹, Orest O Kayder¹, Teena Chopra², Hani Abujudeh¹

Affiliations

¹ Division of Radiology, Detroit Receiving Hospital/University Health Network 3L8, 4201 St Antoine Blvd, Detroit, MI 48201, USA.
² Division of Infectious Diseases, Detroit Medical Center, Detroit Receiving Hospital/University Health Network 2E, 4201 St Antoine Blvd, Detroit, MI 48201, USA.

Abstract

On December 2020, the US Food and Drug Administration issued the first emergency use authorization for a vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report development of superficial thrombophlebitis in the ipsilateral breast of a 43-year-old female 7 days after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine. Given that this is the first case of superficial thrombophlebitis in the breast shortly after mRNA vaccination for COVID-19 reported to our knowledge, we suggest that this may be a rare vaccine-related event.

Keywords: COVID; COVID19 vaccine; Mondor’s disease; mRNA vaccination; superficial thrombophlebitis.

Publication types

Case Reports